S&P DJI Announces March 2022 Quarterly Rebalance
Filed with ASX · · 10 pages · English
Story so far
Earlier from Cyclopharm
- Cyclopharm USFDA Update
- Half Year 2021 Financial Results
- CYC First Half Trading Update
- Managing Directors Address to Shareholders
- CYC 2021 AGM Presentation
Later from Cyclopharm
- 1H 2022 Business Update - Record Revenues
- Technegas Used In Multicenter COVID Study
- Half Year 2022 Results
- Cyclopharm Receives $1.64m R&D Refund
- Dividend/Distribution - CYC
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm